These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

185 related items for PubMed ID: 32694317

  • 1. Pharmacotherapy of attention-deficit hyperactivity disorder: common quandaries, dilemmas and challenges.
    Mosheva M, Dar N, Rima Madi L, Weizman A, Gothelf D.
    Int Clin Psychopharmacol; 2020 Nov; 35(6):300-304. PubMed ID: 32694317
    [Abstract] [Full Text] [Related]

  • 2. A Naturalistic Comparison of Methylphenidate and Risperidone Monotherapy in Drug-Naive Youth With Attention-Deficit/Hyperactivity Disorder Comorbid With Oppositional Defiant Disorder and Aggression.
    Masi G, Manfredi A, Nieri G, Muratori P, Pfanner C, Milone A.
    J Clin Psychopharmacol; 2017 Oct; 37(5):590-594. PubMed ID: 28806385
    [Abstract] [Full Text] [Related]

  • 3. Comorbid anxiety and social avoidance in treatment of severe childhood aggression: response to adding risperidone to stimulant and parent training; mediation of disruptive symptom response.
    Arnold LE, Gadow KD, Farmer CA, Findling RL, Bukstein O, Molina BS, Brown NV, Li X, Rundberg-Rivera EV, Bangalore S, Buchan-Page K, Hurt EA, Rice R, McNamara NK, Aman MG.
    J Child Adolesc Psychopharmacol; 2015 Apr; 25(3):203-12. PubMed ID: 25885010
    [Abstract] [Full Text] [Related]

  • 4. Atypical antipsychotics for disruptive behaviour disorders in children and youths.
    Loy JH, Merry SN, Hetrick SE, Stasiak K.
    Cochrane Database Syst Rev; 2012 Sep 12; (9):CD008559. PubMed ID: 22972123
    [Abstract] [Full Text] [Related]

  • 5. Risperidone effects in the presence/absence of psychostimulant medicine in children with ADHD, other disruptive behavior disorders, and subaverage IQ.
    Aman MG, Binder C, Turgay A.
    J Child Adolesc Psychopharmacol; 2004 Sep 12; 14(2):243-54. PubMed ID: 15319021
    [Abstract] [Full Text] [Related]

  • 6. Attendance and Engagement in Parent Training Predict Child Behavioral Outcomes in Children Pharmacologically Treated for Attention-Deficit/Hyperactivity Disorder and Severe Aggression.
    Joseph HM, Farmer C, Kipp H, Kolko D, Aman M, McGinley J, Arnold LE, Gadow KD, Findling RL, Molina BSG.
    J Child Adolesc Psychopharmacol; 2019 Mar 12; 29(2):90-99. PubMed ID: 30592635
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Risperidone Added to Psychostimulant in Children with Severe Aggression and Attention-Deficit/Hyperactivity Disorder: Lack of Effect on Attention and Short-Term Memory.
    Farmer CA, Epstein JN, Findling RL, Gadow KD, Arnold LE, Kipp H, Kolko DJ, Butter E, Schneider J, Bukstein OG, McNamara NK, Molina BS, Aman MG.
    J Child Adolesc Psychopharmacol; 2017 Mar 12; 27(2):117-124. PubMed ID: 27348211
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Understanding Chronic Aggression and Its Treatment in Children and Adolescents.
    Magalotti SR, Neudecker M, Zaraa SG, McVoy MK.
    Curr Psychiatry Rep; 2019 Nov 18; 21(12):123. PubMed ID: 31741142
    [Abstract] [Full Text] [Related]

  • 11. Managing ADHD and disruptive behaviour disorders with combination psychostimulant and antipsychotic treatment.
    Elbe D, Barr AM, Honer WG, Procyshyn RM.
    J Psychiatry Neurosci; 2014 May 18; 39(3):E32-3. PubMed ID: 24758945
    [No Abstract] [Full Text] [Related]

  • 12. [Pharmacotherapy of attention-deficit/hyperactivity disorder (ADHD) and comorbid disorders].
    Wiesegger G, Kienbacher C, Pellegrini E, Scheidinger H, Vesely C, Bangerl W, Friedrich M.
    Neuropsychiatr; 2007 May 18; 21(3):187-206. PubMed ID: 17915180
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Predictors of concomitant use of antipsychotics and stimulants and its impact on stimulant persistence in pediatric attention deficit hyperactivity disorder.
    Bali V, Kamble PS, Aparasu RR.
    J Manag Care Spec Pharm; 2015 Jun 18; 21(6):486-98. PubMed ID: 26011550
    [Abstract] [Full Text] [Related]

  • 16. Not just another antipsychotic-for-conduct-problems trial.
    Blader JC.
    J Am Acad Child Adolesc Psychiatry; 2014 Jan 18; 53(1):17-20. PubMed ID: 24342382
    [No Abstract] [Full Text] [Related]

  • 17. The Relationship between Acute Dyskinesia with a Single Dose of Methylphenidate and Recent Risperidone Discontinuation in a Child with Attention-Deficit/Hyperactivity Disorder.
    Ince E, Algedik P, Demirdogen ES, Emul M, Demir T.
    J Child Adolesc Psychopharmacol; 2015 May 18; 25(4):378-9. PubMed ID: 25920038
    [No Abstract] [Full Text] [Related]

  • 18. A naturalistic study of predictors and risks of atypical antipsychotic use in an attention-deficit/hyperactivity disorder clinic.
    Weiss M, Panagiotopoulos C, Giles L, Gibbins C, Kuzeljevic B, Davidson J, Harrison R.
    J Child Adolesc Psychopharmacol; 2009 Oct 18; 19(5):575-82. PubMed ID: 19877982
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.